Andrew Evens: For older HL patients we provide personalized treatment recommendations and post-acute survivorship considerations

Andrew Evens, Deputy Director for Clinical Services, Rutgers Cancer Institute of New Jersey, recently shared on LinkedIn:

“Please see below a link to our manuscript recently published in the American Society of Hematology (ASH) 2023 educational proceedings entitled ‘Hodgkin lymphoma treatment for older persons in the modern era’.

It was great to collaborate on this work with Rutgers Cancer Institute of New Jersey senior Hematology/Oncology fellow and junior faculty member, Dr. Marshall McKenna and Dr. Claire Yun Kyoung Ryu Tiger MD, PhD, respectively, as well as a wonderful cardio-oncology colleague, Tufts Medical Center, Dr. Jenica Upshaw.

There has been a renewed effort globally in the study of older Hodgkin lymphoma (HL) patients that has generated a multitude of new data, which we critically analyze and provide personalized treatment recommendations and post-acute survivorship considerations.

In addition, this topic was presented at the main HL oral education session in San Diego last month at ASH, together with fantastic colleagues/lymphoma experts: the University of North Carolina at Chapel Hill, Dr. Natalie Grover and MD Anderson Cancer Center, Dr. Sairah Ahmed. You can find their associated manuscripts (among others) here.”
Read further.

Source: Andrew Evens/LinkedIn